Memorial Sloan Kettering Cancer Center: Fallopian Tube Neoplasms trials

The registry lists 27 Fallopian Tube Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 8Phase 2 11No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive SurgeryRecruitingNCT06290193Phase 2
• A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)RecruitingNCT05429970Not applicable
• Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesCompletedNCT01974765Phase 2Results posted
• Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01767675Phase 2Results posted
• Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT01248962Phase 2Results posted
• Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With BevacizumabCompletedNCT01223235Not applicableResults posted
• Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of LifeCompletedNCT00870233Results posted
• Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT00588237Phase 2Results posted
• Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)CompletedNCT00562640Phase 1Results posted
• Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second RemissionTerminatedNCT00522301Phase 2Results posted
• Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant ChemotherapyActive, not recruitingNCT04204811Not applicable
• Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyCompletedNCT02928549
• Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT02121990Phase 1
• Structural and Functional Imaging and Cognitive Functions in Ovarian CancerCompletedNCT01591772
• Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian CancerCompletedNCT01471483
• Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian CancerCompletedNCT01442051Not applicable
• Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally InvasiveCompletedNCT01262040Not applicable
• Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNCT00058435Phase 1
• Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
• TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00022347Phase 2
• Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00021034Phase 1
• CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal CancerCompletedNCT00017017Phase 1/2
• Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or PeritoneumCompletedNCT00012090Phase 2
• Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00006041Phase 1
• Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00004012Phase 2
• Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00003358Phase 1
• Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00003345Phase 2